RTA Laboratuvarlari Biyolojik Total Assets

Latest as of June 2025: TL2.23 Billion TRY ≈ $49.90 Million USD

RTA Laboratuvarlari Biyolojik total assets. Based on the latest financial reports, RTA Laboratuvarlari Biyolojik (RTALB) holds total assets worth TL2.23 Billion TRY (≈ $49.90 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see RTALB market cap overview for the company's overall valuation and market capitalisation.

Total Assets of RTA Laboratuvarlari Biyolojik (2010–2024)

Total assets of RTA Laboratuvarlari Biyolojik from 2010 to 2024. This chart illustrates how RTA Laboratuvarlari Biyolojik's total assets have evolved over time, based on quarterly financial data. See RTALB stock price and chart for real-time trading data and today's change.

RTA Laboratuvarlari Biyolojik - Asset Composition Analysis

RTA Laboratuvarlari Biyolojik Total Assets Breakdown (December 2024)

RTA Laboratuvarlari Biyolojik total assets breakdown as of December 2024. RTA Laboratuvarlari Biyolojik's total assets of TL2.23 Billion consist of 8.1% current assets and 91.9% non-current assets.

Asset Category	Amount (TRY)	% of Total Assets
Cash & Equivalents	TL0.00	0.3%
Accounts Receivable	TL60.30 Million	3.1%
Inventory	TL40.86 Million	2.1%
Property, Plant & Equipment	TL0.00	0.0%
Intangible Assets	TL131.16K	0.0%
Goodwill	TL0.00	0.0%

Asset Composition Trend (2010–2024)

This chart illustrates how RTA Laboratuvarlari Biyolojik's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore RTA Laboratuvarlari Biyolojik (RTALB) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: RTA Laboratuvarlari Biyolojik's current assets represent 8.1% of total assets in 2024, an increase from 0.0% in 2010.
Cash Position: Cash and equivalents constituted 0.3% of total assets in 2024, down from 32.5% in 2010.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2010.
Asset Diversification: The largest asset category is accounts receivable at 3.1% of total assets.

RTA Laboratuvarlari Biyolojik Competitors by Total Assets

Key competitors of RTA Laboratuvarlari Biyolojik based on total assets are shown below.

Company	Country	Total Assets
Samsung Biologics Co Ltd KO:207940	Korea	₩12.65 Trillion
Verona Pharma plc F:I9SA	Germany	€572.87 Million
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	China	CN¥20.70 Billion
Immunovant Inc NASDAQ:IMVT	USA	$852.49 Million
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	China	CN¥8.59 Billion
Tubize-Fin BR:TUB	Belgium	€1.99 Billion
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	China	CN¥37.46 Billion
Amicus Therapeutics Inc NASDAQ:FOLD	USA	$949.87 Million

RTA Laboratuvarlari Biyolojik - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.24	1.60	1.99
Quick Ratio	1.84	1.18	1.18
Cash Ratio	0.00	0.00	0.00
Working Capital	TL95.63 Million	TL77.71 Million	TL59.76 Million

RTA Laboratuvarlari Biyolojik - Advanced Valuation Insights

This section examines the relationship between RTA Laboratuvarlari Biyolojik's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	0.83
Latest Market Cap to Assets Ratio	0.01
Asset Growth Rate (YoY)	6.5%
Total Assets	TL1.92 Billion
Market Capitalization	$22.17 Million USD

Valuation Analysis

Below Book Valuation: The market values RTA Laboratuvarlari Biyolojik's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: RTA Laboratuvarlari Biyolojik's assets grew by 6.5% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for RTA Laboratuvarlari Biyolojik (2010–2024)

The table below shows the annual total assets of RTA Laboratuvarlari Biyolojik from 2010 to 2024.

Year	Total Assets	Change
2024-12-31	TL1.92 Billion ≈ $43.03 Million	+6.46%
2023-12-31	TL1.80 Billion ≈ $40.42 Million	+143.79%
2022-12-31	TL740.21 Million ≈ $16.58 Million	+34.00%
2021-12-31	TL552.40 Million ≈ $12.37 Million	+115.34%
2020-12-31	TL256.52 Million ≈ $5.75 Million	+161.33%
2019-12-31	TL98.16 Million ≈ $2.20 Million	+48.61%
2018-12-31	TL66.05 Million ≈ $1.48 Million	+4.69%
2017-12-31	TL63.09 Million ≈ $1.41 Million	+3.61%
2016-12-31	TL60.89 Million ≈ $1.36 Million	-1.17%
2015-12-31	TL61.61 Million ≈ $1.38 Million	+25.63%
2014-12-31	TL49.04 Million ≈ $1.10 Million	+67.08%
2013-12-31	TL29.35 Million ≈ $657.41K	+43.53%
2012-12-31	TL20.45 Million ≈ $458.03K	+23.16%
2011-12-31	TL16.60 Million ≈ $371.89K	-1.50%
2010-12-31	TL16.86 Million ≈ $377.55K	--

About RTA Laboratuvarlari Biyolojik

IS:RTALB Turkey Biotechnology

Market Cap

$22.17 Million

TL990.00 Million TRY

Market Cap Rank

#24593 Global

#387 in Turkey

Share Price

TL1.98

Change (1 day)

+0.51%

52-Week Range

TL1.86 - TL4.71

All Time High

TL29.60